{"id":"insulin-aspart-iasp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin aspart is a genetically engineered insulin analog with a single amino acid substitution (proline to aspartic acid at position 28 of the B chain) that reduces self-association and enables faster absorption from subcutaneous injection sites compared to human insulin. It binds to insulin receptors on muscle, fat, and liver cells to facilitate glucose transport into cells and promote anabolic metabolism, effectively lowering blood glucose levels.","oneSentence":"Insulin aspart is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:09.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT04620967","phase":"PHASE4","title":"Fast-Acting Insulin Aspart and Insulin Pump Settings","status":"UNKNOWN","sponsor":"Kirsten Nørgaard","startDate":"2021-02-01","conditions":"Type 1 Diabetes","enrollment":40},{"nctId":"NCT02906917","phase":"PHASE3","title":"A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-20","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":532},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT02034513","phase":"PHASE3","title":"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":501},{"nctId":"NCT01774565","phase":"NA","title":"Closed-loop Insulin Delivery in the General Ward","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2016-08","conditions":"Diabetes Mellitus","enrollment":43},{"nctId":"NCT01713530","phase":"PHASE3","title":"A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-02-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":274},{"nctId":"NCT02420262","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-07-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01814137","phase":"PHASE3","title":"A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01486966","phase":"PHASE4","title":"Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2011-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT01388361","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT01486914","phase":"PHASE1","title":"Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-01-19","conditions":"Diabetes, Healthy","enrollment":28},{"nctId":"NCT01467141","phase":"PHASE4","title":"Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":26},{"nctId":"NCT01542489","phase":"","title":"Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-10","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01536028","phase":"PHASE1","title":"Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT01490112","phase":"","title":"Surveillance Study of NovoRapid® for New Drug Re-examination","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1239},{"nctId":"NCT01487369","phase":"","title":"Special Survey of Production of Insulin Aspart Specific Antibody","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-04","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":204},{"nctId":"NCT01773798","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT00992537","phase":"PHASE1","title":"Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-10","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":27},{"nctId":"NCT01173926","phase":"PHASE1","title":"Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-07","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":27},{"nctId":"NCT00497536","phase":"PHASE4","title":"Pharmacokinetics of IAsp Following CSII in Patients With T1DM","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-07","conditions":"Type 1 Diabetes Mellitus","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Insulin Aspart (IAsp)","genericName":"Insulin Aspart (IAsp)","companyName":"University of Aarhus","companyId":"university-of-aarhus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}